KVUE · Kenvue Inc.

Track KVUE — free

$19.31 -0.25 (-1.28%) At close · Oct 30

Rebalance outlook locked

Market Cap

$37.11B

1.92B

Volume · Oct 30 66.6M Avg daily vol (3M) 22.71M

Up next

Next earnings call

Jan 26, 2027 Est · unconfirmed · in 12 wks

Q2 2025 earnings call transcript

call held Aug 7, 2025

Latest documents

what the company just published, in one sentence each

2026

Nov 4

Current report 8-K

Change to shareholders' rights AI summary on its way

Nov 2

Current report 8-K Events of Nov 1

Ended a material agreement, Completed an acquisition or sale of assets, Delisting notice or listing transfer, Change to shareholders' rights, Change in control, Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Other events

Oct 30

Quarterly report 10-Q FY2026 Q3, ended Sep 27

Sales rise 3.6%; K-C acquisition shareholder-approved

Kenvue reported nine-month net sales of $11.8 billion, up 3.6%, for the fiscal period ended September 27, 2026. Shareholders approved the pending K-C acquisition, with each Kenvue share receiving 0.14625 K-C shares and $3.50 in cash.

Revenue $3.89B ▲ 3.2% Net income $430M ▲ 8.0% Diluted EPS $0.22 ▲ 4.8%

Read from the MD&A section

4 source passages

At Kenvue, our purpose is to realize the extraordinary power of everyday care. Net sales were $11.8 billion and $11.3 billion for the fiscal nine months ended September 27, 2026 and September 28, 2025, respectively, an increase of $406 million, or 3.6%. Company shareholders will receive 1) 0.14625 shares of K-C Common Stock and 2) $3.50 in cash for each share of the Company they own. On January 29, 2026, our shareholders approved the adoption of the Merger Agreement and K-C’s shareholders approved the issuance of K-C Common Stock in connection with the Pending Transaction, in each case at a special meeting of shareholders held for that purpose. Open the document at this passage

Oct 30

Current report 8-K

Financial results

Kenvue Inc. reported fiscal third-quarter net sales growth of 3.2%, organic sales growth of 2.9% and diluted EPS of $0.22 for the period ended September 27, 2026. Free cash flow for fiscal nine months rose to $1.6 billion from $1.0 billion.

Oct 13

Current report 8-K Events of Oct 9

Entered into a material agreement

Kenvue Inc. entered a Third Supplemental Indenture dated October 9, 2026, obtaining holder consents to amend its existing note series for Kimberly-Clark’s exchange offers. The amendments become operative upon settlement and remove substantially all restrictive covenants.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

$15.53B

Trailing 12 months

Net income (TTM)

$1.69B

Trailing 12 months

Revenue growth YoY

+3.2%

Year over year

Operating margin

17.4%

Trailing 12 months

P / E (TTM)

22.2

Trailing earnings · reciprocal yield 4.5%

FCF yield

6.3%

TTM · current market cap

Return on invested capital

11.4%

Trailing 12 months

Net cash

−$7.17B

Latest balance sheet

Dividend yield

5.4%

Trailing 12 months

Shares change YoY

+0.2%

Year over year · more shares

Price change (1Y)

+35.6%

Trailing year

Short interest

2.9%

Latest settlement · 2.7 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

▼0.1% $3.66B $293.00M '24 Q4* ▼3.9% $3.74B $322.00M '25 Q1 ▼4% $3.84B $420.00M '25 Q2 ▼3.5% $3.76B $398.00M '25 Q3 ▲3.2% $3.78B $330.00M '25 Q4* ▲4.5% $3.91B $474.00M '26 Q1 ▲3% $3.96B $456.00M '26 Q2 LATEST ▲3.2% $3.89B $430.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Research

our published analysis of this company

Scientific Research October 27, 2026

Not Every Short Is a Bet: The S&P 500's Most-Shorted Stocks

Ten of the 25 most-shorted S&P 500 stocks have a stock deal, convertible notes, forward share sales or a mandatory convertible in their SEC filings, each a standard source of hedged short selling. Kimberly-Clark and Medtronic show how fast deal trades can push a position up.

Equibles Rating

blended score · not investment advice

Overall

Strong Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very Low

Market backdrop VIX 16.6 · calm Equity put/call 0.44

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +6%

above

Price vs 50-day avg +5%

above

RSI (14) 60

neutral

MACD trend Positive

52-week position 90%

near high

Momentum

relative strength

Very Strong

1-month return +12%

trailing

6-month return +12%

trailing

YTD return +12%

this year

Relative strength +10%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $18 › 200d $18 — 50d above 200d

Institutional flow Distributing

439 of 1,022 funds reported for Sep 30 · net -9.1M sh shares · +47 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.90% of shares out · ▼ -3.4% MoM · 2.7 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

1,022 holders — mid 3-yr range

Squeeze score 47

elevated · 0–100

Fundamentals

Strong

Revenue growth −2%

Y/Y

Gross margin 58%

expanding

EPS growth +41%

Y/Y

Free cash flow $1.7B

Valuation P/E 21.9

below peers

Balance sheet $7.5B

net debt

Quant / Vol

risk profile

Very Low

Volatility 24%

annualized · 1-yr

Max drawdown −13%

past year

ATR 2.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Oct 30, 2026

Pre-tax restructuring expenses and other charges · fiscal year 2026 Initiated $250M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+6% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

60 Neutral

MACD trend

Positive Bullish

52-week position

90% Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $18 › 200d $18 — 50d above 200d

Institutional flow Distributing

439 of 1,022 funds reported for Sep 30 · net -9.1M sh shares · +47 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.90% of shares out · ▼ -3.4% MoM · 2.7 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Steady

1,022 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $14 Now $19 · 90% Range high $20

vs 200-day avg +6% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted Effective tax rate (non-GAAP) non-GAAP	25%	Fiscal Nine Months Ended September 27, 2026	—
Adjusted gross profit margin non-GAAP	61.5%	Third quarter 2026	—
Adjusted operating income (non-GAAP) non-GAAP	$2.66B	Fiscal Nine Months Ended September 27, 2026	—
Adjusted operating income margin non-GAAP	21.9%	Third quarter 2026	—
EBITDA (non-GAAP) non-GAAP	$2.88B	Fiscal Nine Months Ended September 27, 2026	—
EBITDA margin (non-GAAP) non-GAAP	24.5%	Fiscal Nine Months Ended September 27, 2026	—
Essential Health Adjusted operating income non-GAAP	$929M	Fiscal Nine Months Ended September 27, 2026	—

Free cash flow non-GAAP	1.6B	Fiscal nine months ended September 27, 2026	—
Gross profit margin non-GAAP	61.5%	Fiscal Three Months Ended September 27, 2026	—
Net income margin non-GAAP	14.6%	Fiscal Three Months Ended September 27, 2026	—
Operating income margin non-GAAP	21.9%	Fiscal Three Months Ended September 27, 2026	—
Organic sales decline non-GAAP	0.5%	Third quarter 2026	—
Self Care Adjusted operating income non-GAAP	$1.67B	Fiscal Nine Months Ended September 27, 2026	—

Skin Health and Beauty Adjusted operating income non-GAAP	$503M	Fiscal Nine Months Ended September 27, 2026	—

Total Adjusted operating income non-GAAP	$3.11B	Fiscal Nine Months Ended September 27, 2026	—

Total restructuring expenses and operating model optimization initiatives	$188M	Fiscal Nine Months Ended September 27, 2026	—

Total separation-related costs	$16M	Fiscal Nine Months Ended September 27, 2026	—

Total separation-related costs, conversion of stock-based awards, and Founder Shares	$20M	Fiscal Nine Months Ended September 27, 2026	—
volume decrease	1.7%	Third quarter 2026	—
volume growth	1.6%	Third quarter 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Household & Personal Products — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
KVUE Kenvue Inc. this stock	$37.11B	+11.9%	-2.1%	21.9	2.9%
PG PROCTER & GAMBLE Co	$389.13B	+16.6%	+3.3%	25.3	1.0%
UL Unilever PLC	$145.80B	+3.5%	—	—	0.0%
CL Colgate Palmolive Co	$78.51B	+24.9%	+1.7%	38.6	2.2%
RBGLY Reckitt Benckiser Group PLC	$48.32B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

1,042

% held: 94.4%
Reported: 439 of 1,022
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

704

View

Short & Settlement

Short Interest Falling

Shares short

55.7M

Days to cover: 2.7d
Change: -2.0M sh

View

Short Volume

Short vol %

23%

As of: Oct 30, 2026

Short Total

View

Fails to Deliver

FTD shares

20.5K

Value: $365.6K
As of: Sep 28, 2026

View

Off-Exchange

Off-exchange %

47.7%

Week of: Sep 28, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Kevin Hern

Amount: $1.0K–$15.0K
Traded: Aug 5, 2026

View

Financials

Revenue (FY)

$15.1B

Net income (FY): $1.5B
EPS diluted: $0.76

View

Buybacks

Authorized

shares 27.0M

View

Filings

SEC Filings

Latest

8-K

Filed: Nov 4, 2026
This year: 20

View

Proposed Sales

Value

$67.0K

Shares: 3.7K
Filed: Jun 10, 2026

View

Earnings & Events

Webcasts

Last webcast

Oct 30, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
KVUE	-1.3%	+12.3%	+12.5%	+9.3%	+11.9%
SPY	-0.6%	-1.8%	+2.2%	-0.9%	+10.8%
vs SPY	-0.8%	+14.1%	+10.2%	+10.3%	+1.1%

Capital returns

Latest dividend

$0.21 / share · ex Sep 21, 2026

Raised 1%

Paid (TTM)

$1.044 / share · 5 payouts

Dividend yield (TTM, derived)

5.41%

Full dividend history

Buyback program · as of Dec 28, 2025

Authorized

shares 27.00M

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1944048 CUSIP 49177J102 13F (30d) 438 filings 401 filers Visit website Investor relations

KVUE · Kenvue Inc.

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns